Skip to main content
Article thumbnail
Location of Repository

Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies

By Omar S. Al-Attas, Nasser M. Al-Daghri, Khalid Al-Rubeaan, Nancy F. da Silva, Shaun Sabico, Sudhesh Kumar, P. G. (Philip G.) McTernan and A. L. (Alison L.) Harte


Introduction\ud Chronic low-grade inflammation is a significant factor in the development of obesity associated diabetes. This is supported by recent studies suggesting endotoxin, derived from gut flora, may be key to the development of inflammation by stimulating the secretion of an adverse cytokine profile from adipose tissue.\ud \ud Aims\ud The study investigated the relationship between endotoxin and various metabolic parameters of diabetic patients to determine if anti-diabetic therapies exerted a significant effect on endotoxin levels and adipocytokine profiles.\ud \ud Methods\ud Fasting blood samples were collected from consenting Saudi Arabian patients (BMI: 30.2 ± (SD)5.6 kg/m2, n = 413), consisting of non-diabetics (ND: n = 67) and T2DM subjects (n = 346). The diabetics were divided into 5 subgroups based on their 1 year treatment regimes: diet-controlled (n = 36), metformin (n = 141), rosiglitazone (RSG: n = 22), a combined fixed dose of metformin/rosiglitazone (met/RSG n = 100) and insulin (n = 47). Lipid profiles, fasting plasma glucose, insulin, adiponectin, resistin, TNF-α, leptin, C-reactive protein (CRP) and endotoxin concentrations were determined.\ud \ud Results\ud Regression analyses revealed significant correlations between endotoxin levels and triglycerides (R2 = 0.42; p < 0.0001); total cholesterol (R2 = 0.10; p < 0.001), glucose (R2 = 0.076; p < 0.001) and insulin (R2 = 0.032; p < 0.001) in T2DM subjects. Endotoxin showed a strong inverse correlation with HDL-cholesterol (R2 = 0.055; p < 0.001). Further, endotoxin levels were elevated in all of the treated diabetic subgroups compared with ND, with the RSG treated diabetics showing significantly lower endotoxin levels than all of the other treatment groups (ND: 4.2 ± 1.7 EU/ml, RSG: 5.6 ± 2.2 EU/ml). Both the met/RSG and RSG treated groups had significantly higher adiponectin levels than all the other groups, with the RSG group expressing the highest levels overall.\ud \ud Conclusion\ud We conclude that sub-clinical inflammation in T2DM may, in part, be mediated by circulating endotoxin. Furthermore, that whilst the endotoxin and adipocytokine profiles of diabetic patients treated with different therapies were comparable, the RSG group demonstrated significant differences in both adiponectin and endotoxin levels. We confirm an association between endotoxin and serum insulin and triglycerides and an inverse relationship with HDL. Lower endotoxin and higher adiponectin in the groups treated with RSG may be related and indicate another mechanism for the effect of RSG on insulin sensitivity

Topics: RC
Publisher: BioMed Central Ltd.
Year: 2009
OAI identifier:

Suggested articles


  1. (2006). A: Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. Diabet Med doi
  2. (2006). A: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab doi
  3. (2003). AL: A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers.
  4. (1993). AL: In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA
  5. (1995). AL: Reconstituted high-density lipoprotein neutralizes gramnegative bacterial lipopolysaccharides in human whole blood. Infect Immun
  6. (2004). Aljada A, Bandyopadhyay A: Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol doi
  7. (2005). Basic approach to managing hyperglycemia for the nonendocrinologist. doi
  8. (2004). BK: Effect of hyperglycemia and hyperinsulinemia on the response of IL-6, TNF-alpha, and FFAs to low-dose endotoxemia in humans. doi
  9. (1998). Chrousos GP: Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion. doi
  10. (2005). Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. Clin Chim Acta doi
  11. (2006). Cohen A: Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. doi
  12. (2003). Current therapeutic options in type 2 diabetes mellitus: a practical approach. Clin Med Res doi
  13. (2005). E: Evidence that acute hyperinsulinaemia increases the cytokine content in essential organs after an endotoxin challenge in a porcine model. Acta Anaesthesiol Scand doi
  14. (1998). Endotoxin-induced alteration in the expression of leptin and beta3-adrenergic receptor in adipose tissue.
  15. (2003). Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. doi
  16. (2004). Graves DT: Influence of diabetes on the exacerbation of an inflammatory response in cardiovascular tissue. Endocrinology doi
  17. (1992). Grunfeld C: Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance.
  18. (2003). H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. doi
  19. H: Global prevalence of diabetes: estimates for the year 2000 and projections for doi
  20. (2005). Hotamisligil GS: Inflammation, stress, and diabetes. doi
  21. (2007). Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. doi
  22. (1993). Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology doi
  23. (1998). Inhibitory effects of hyperglycaemia on fed jejunal motility: potential role of hyperinsulinaemia. doi
  24. (1989). Insulin modulates rat intestinal glucose transport: effect of hypoinsulinemia and hyperinsulinemia.
  25. (1993). JH: Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. doi
  26. (1991). JH: Chylomicrons can inhibit endotoxin activity in vitro. doi
  27. (2006). KH: Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes doi
  28. (1996). KR: Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. doi
  29. (2003). Li JS: Influence of acute hyperglycemia in human sepsis on inflammatory cytokine and counterregulatory hormone concentrations.
  30. (1985). Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J doi
  31. (2005). LJ: Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin doi
  32. (2005). M: IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med doi
  33. (2007). McTernan PG: The in vitro effects of resistin on the innate immune signaling pathway in isolated human subcutaneous adipocytes. doi
  34. (2007). Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. doi
  35. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes doi
  36. (2003). Nutrition-related health patterns in the Middle East.
  37. (2007). Obesity and diabetes in the developing world – a growing challenge. doi
  38. (1994). P: LPSinduced release of IL-1 beta, IL-6, IL-8, TNF-alpha and sCD14 in whole blood and PBMC from persons with high or low levels of HDL-lipoprotein. Cytokine doi
  39. (2000). Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res doi
  40. (1990). Pyorala K: Adverse effects of obesity on lipid and lipoprotein levels in insulin-dependent and non-insulindependent diabetes. Metabolism doi
  41. (2003). Ricart W: CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. doi
  42. (2007). Role of Bacterial Endotoxin in Chronic Heart Failure: the Gut of the Matter. Shock doi
  43. (2007). S: Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. doi
  44. (1994). SD: Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. doi
  45. (1995). SD: Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPSbinding protein and reconstituted high density lipoprotein. J Exp Med doi
  46. (1998). Suffredini AF: Circulating leptin levels during acute experimental endotoxemia and antiinflammatory therapy in humans. doi
  47. (2004). Sun ZX: [Effects of rosiglitazone on serum leptin and insulin resistance in patients with Type 2 diabetes]. Zhong Nan Da Xue Xue Bao Yi Xue Ban
  48. (2000). The detection and interpretation of endotoxaemia. Intensive Care Med doi
  49. (2006). The dysregulated adipose tissue: a connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosis. Nutr Metab Cardiovasc Dis doi
  50. (2005). Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol Res doi
  51. (2004). Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. doi
  52. (2005). Wood IS: Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans doi
  53. (2007). Yeh ET: Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. Subcell Biochem

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.